FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)

View source ↗

Summary

FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• TRUXIMA (rituximab-abbs)

Snippet

SUPPL AP for TRUXIMA (RITUXIMAB-ABBS)